search

Active clinical trials for "Adenocarcinoma"

Results 1671-1680 of 2249

Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma

CarcinomaNon-Small-Cell Lung

Phase I study. To determine the MTD (Maximum Tolerated Dose) of nintedanib + weekly Docetaxel in patients with locally advanced or metastatic lung adenocarcinoma after failure of platinum-based first line chemotherapy.

Completed7 enrollment criteria

The βIG-H3 Protein: a New Marker in PANCreatic Adenocarcinoma (BIGHPANC)

Pancreas Adenocarcinoma

The primary objective of this trial is to evaluate the correlation between the intensity of the protein big-h3 expression at tumoural microenvironment and the TNM/UICC staging (from I to IV) of pancreatic adenocarcinoma lesion.

Active6 enrollment criteria

Focused Stereotactic Radiation Treatment of Prostatic Adenocarcinoma

Prostate Cancer

Focused stereotactic radiation treatment of localized prostatic adenocarcinoma. in order to quantify the delay between the focused treatment and the salvage procedure.

Active2 enrollment criteria

Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam

Prostate Adenocarcinoma

This trial examines if a prostate magnetic resonance spectroscopic imaging can be performed on a 3T scanner using an investigational contrast called hyperpolarized 13-C pyruvate for the development of a clinical prostate cancer exam. 3T refers to the strength of the magnetic resonance spectroscopic imaging (MRSI) machine. MRSI is a magnetic resonance imaging (MRI) technique that can show certain chemical differences in healthy and diseased prostate tumor tissue compared to standard multiparametric MRI that may not detect the tumor. Hyperpolarized (HP) 13-C pyruvate is a contrast drug that may help the scanner see the tumor site better during imaging. Hyperpolarization of 13-C pyruvate may allow pyruvate and its metabolites to be detected upon injection, which in turn, allow the prostate cancer to be found and treated.

Active9 enrollment criteria

Survey Study on Barrett's Esophagus Screening

Gastroesophageal Reflux DiseaseBarrett's Esophagus1 more

The goal of this study is to optimize Barrett's Esophagus (BE) screening to reduce the incidence, morbidity, and mortality of Esophageal Adenocarcinoma (EAC).

Active8 enrollment criteria

ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral...

Prostate Adenocarcinoma

This study will determine the delayed neurotoxicity (12 months) of a hypofractionated high dose irradiation (3 Gy x 9) associated with zoledronic acid. The administration of zoledronic acid repeat dosages defined under the Authorisation on the Market. All patients receive a total dose of 27 Gy divided into 3 fractions of 9 Gy performed at least 48 hours apart each, for a treatment to J1, J3 and J5.

Completed16 enrollment criteria

Docetaxel in Locally Advanced Gastric Adenocarcinoma

Stomach Neoplasms

Study objectives: To determine Ro resection rate of Docetaxel, cisplatin and fluorouracil combination for the treatment of neoadjuvant gastric carcinoma.

Completed25 enrollment criteria

Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma

AdenocarcinomaBronchiolo-Alveolar

To evaluate among patients with untreated advanced ADC-CBA, impact on the disease control rate after 4 months treatment of an early therapeutic permutation with the first month in the absence of stabilization or objective answer.

Completed2 enrollment criteria

Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired...

Lung Adenocarcinoma

The purpose of this study is to test if cetuximab (Erbitux) can shrink lung cancers that initially became smaller after taking erlotinib and then started to get bigger despite continuing treatment. Cetuximab is a medicine approved by the U.S. Food and Drug administration for treatment of head and neck and colon cancer. The goal of the phase I portion of this trial is to find out the highest dose of cetuximab that can be taken together with erlotinib. This study will also give an idea of how well cetuximab shrinks lung cancer when given with erlotinib. The purpose of this study is to test if cetuximab (Erbitux) can shrink lung cancers that initially became smaller after taking erlotinib or gefitinib and then started to get bigger despite continuing treatment. Cetuximab is a medicine approved by the U.S. Food and Drug administration for treatment of head and neck and colon cancer. The goal of this phase is to determine if cetuximab given with erlotinib causes lung cancers to shrink in size.

Completed24 enrollment criteria

Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal...

Colorectal AdenocarcinomaLiver Metastases

When colon or rectal cancer has spread to the liver, the cancer in the liver can sometimes be removed surgically. However, the cancer has a chance or reoccurring in the liver or elsewhere in the body. This study will determine if giving chemotherapy treatment before the surgery can reduce the chances that the cancer will come back.

Completed18 enrollment criteria
1...167168169...225

Need Help? Contact our team!


We'll reach out to this number within 24 hrs